Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors, Sarcoma
In brief
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with recurrent or progressive meningioma.
Key facts
- Study ID
- NCT00348790
- Run by
- Northwestern University
- People needed
- 25
- Starts
- 2006-05-01
- Expected to finish
- 2013-07-01
- Last updated by the study team
- 2018-10-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hematology-Oncology Associates of Illinois — Chicago, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- University Cancer Center at University of Washington Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.